# Current Applications and Immunological Considerations of Salmonella enterica Serovar Typhimurium as a Vaccine Vector

**Authors:** Adam S. Hassan, Kaitlin Winter, Charles M. Dozois, Brian J. Ward, Momar Ndao

PMC · DOI: 10.3390/microorganisms14020492 · Microorganisms · 2026-02-18

## TL;DR

This review explores how Salmonella Typhimurium can be used as a vaccine vector to stimulate immune responses in the gut.

## Contribution

The paper provides a comprehensive overview of S. Typhimurium's immunological potential and recent engineering strategies for vaccine development.

## Key findings

- S. Typhimurium targets the intestinal mucosa and activates both innate and adaptive immune responses.
- Emerging strategies include delayed attenuation and chromosomal integration of antigens for improved vaccine vectors.
- Applications span viral, bacterial, and parasitic pathogens with shared immunological outcomes.

## Abstract

Live attenuated Salmonella enterica serovar Typhimurium has been investigated for decades as an orally delivered vaccine vector due to its ability to target the intestinal mucosa and engage both innate and adaptive immune responses. In humans, S. Typhimurium infection is largely restricted to the gastrointestinal tract, distinguishing it from Salmonella Typhi and providing a rationale for its use in mucosal vaccine strategies. In this review, we discuss the biological features of S. Typhimurium that support its use as a vaccine vector and summarize current understanding of the immune responses generated during wild-type infection, including innate activation and downstream T cell and B cell responses. We compare key biological differences between Salmonella Typhi and S. Typhimurium and outline emerging vector design strategies, including delayed attenuation and chromosomal integration of heterologous antigens. We then review applications of attenuated S. Typhimurium vectors targeting viral, bacterial, and parasitic pathogens, highlighting shared immunological outcomes and design principles across platforms. Finally, we discuss recent advances in vector engineering, including chromosomal integration of heterologous antigens, as well as remaining gaps in knowledge related to the durability of immune responses and translational considerations.

## Full-text entities

- **Diseases:** Leishmania donovani infection (MESH:D007896), cancer (MESH:D009369), measles, mumps (MESH:D009107), injury to (MESH:D014947), inflammatory (MESH:D007249), cestode (MESH:D002590), protozoan infections (MESH:D011528), S. Typhi infection (MESH:D014437), enteropathy (MESH:C538273), Salmonella infection (MESH:D012480), cholera (MESH:D002771), trematode infections (MESH:D014201), rubella (MESH:D012409), gastrointestinal (MESH:D005767), COVID-19 (MESH:D000086382), S. Typhimurium infection (MESH:D007239), viral diseases (MESH:D014777), impaired neutrophil function (MESH:C564275), ascariasis (MESH:D001196), malnutrition (MESH:D044342), Helminth co-infection (MESH:D060085), Infectious Diseases (MESH:D003141), typhoid fever (MESH:D014435), smallpox (MESH:D012899), HIV infection (MESH:D015658), helminth parasites (MESH:D010272), tuberculosis (MESH:D014376), poliomyelitis (MESH:D011051), enteric infections (MESH:D004751), bacterial (MESH:D001424)
- **Chemicals:** Ty21a (MESH:C072772), lipid A (MESH:D008050), adenine (MESH:D000225), CpG (MESH:C015772), TSOL18 (-), ROS (MESH:D017382), D-xylose (MESH:D014994), Alhydrogel (MESH:D000536), LPS (MESH:D008070), albendazole (MESH:D015766)
- **Species:** Lactobacillus (genus) [taxon 1578], Salmonella enterica subsp. enterica serovar Typhi (no rank) [taxon 90370], Mus musculus (house mouse, species) [taxon 10090], Schistosoma japonicum (species) [taxon 6182], Escherichia coli (E. coli, species) [taxon 562], Foot-and-mouth disease virus (no rank) [taxon 12110], Salmonella enterica subsp. enterica serovar Typhimurium (no rank) [taxon 90371], H1N1 subtype (serotype) [taxon 114727], Human immunodeficiency virus 1 (no rank) [taxon 11676], Sus scrofa (pig, species) [taxon 9823], Streptococcus pneumoniae (species) [taxon 1313], Severe acute respiratory syndrome coronavirus 2 (no rank) [taxon 2697049], Schistosoma mansoni (species) [taxon 6183], Salmonella enterica (species) [taxon 28901], Clostridioides difficile (species) [taxon 1496], Homo sapiens (human, species) [taxon 9606], Lactococcus (lactic streptococci, genus) [taxon 1357], Staphylococcus aureus (species) [taxon 1280], Trichinella spiralis (species) [taxon 6334], Salmonella bongori (species) [taxon 54736], Echinococcus granulosus (species) [taxon 6210], Orthomyxoviridae (family) [taxon 11308], Cryptosporidium parvum (species) [taxon 5807], Taenia solium (pig tapeworm, species) [taxon 6204], H5N1 subtype (serotype) [taxon 102793], Enterobacteriaceae (enterobacteria, family) [taxon 543]
- **Cell lines:** VNP20009 — Homo sapiens (Human), Induced pluripotent stem cell (CVCL_HG97), YS1646 — Homo sapiens (Human), Xeroderma pigmentosum, complementation group E, Transformed cell line (CVCL_7327), Ty21a — Homo sapiens (Human), NUT carcinoma, Cancer cell line (CVCL_3220), C57BL/6 — Mus musculus (Mouse), Transformed cell line (CVCL_C0MU), YS72 — Rattus norvegicus (Rat), Rat sarcoma, Cancer cell line (CVCL_4U54)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12943062/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12943062/full.md

## References

102 references — full list in the complete paper: https://tomesphere.com/paper/PMC12943062/full.md

---
Source: https://tomesphere.com/paper/PMC12943062